Musoro wenhaurirano uchave weNovavax 'COVID-NanoFlu™ Musanganiswa Vaccine, uyo unosanganisa kambani inodzokorora nanoparticle protein-based COVID-19 uye NanoFlu ™ vaccine vaccine neMatrix-M™ adjuvant mune imwe chete mafomu.
Session details ndezvizvi:
| Zuva: Chitatu, Gumiguru 20, 2021 |
| Nguva: 11:30 am - 12:00 pm Central European Time (CET) / |
| 5:30 am - 6:00 am Eastern Daylight Time (EDT) |
| Musoro: Gadziridzo paNovavax 'NanoFlu vaccine uye COVID-19-NanoFlu Combination Vaccine kuvandudza |
| Novavax Mutori wechikamu: Vivek Shinde, MD, Mutevedzeri weMutungamiri, Clinical Development |
Iyo kambani inodzokorodza tekinoroji tekinoroji inosanganisa simba nekumhanyisa kwemajini engineering kuti ibudise zvakanyanya immunogenic nanoparticles akagadzirirwa kugadzirisa nekukurumidza hutano hwepasirese. Novavax iri kuita zvekunonoka-nhanho kiriniki miedzo yeNVX-CoV2373, yayo yekudzivirira yekudzivirira SARS-CoV-2, hutachiona hunokonzera COVID-19. NanoFlu™, iyo quadrivalent furuwenza nanoparticle vaccine, yakasangana nezvinangwa zvese zvakakosha muyedzo yekiriniki yeChikamu chechitatu muvakuru vakuru. Vese vari vaviri vaccine vaccine vanosanganisira Novavax 'proprietary saponin-based Matrix-M™ adjuvant yekusimudzira mhinduro yekudzivirira uye kukurudzira huwandu hwakanyanya hwekudzivirira masoja ekudzivirira chirwere.
ZVOKUBVA MUNYAYA INO:
- NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
- The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.
- Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
